- Home
- PRAA vs MNPR Comparison
PRAA vs MNPR Comparison
Compare PRAA & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRAA | MNPR |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.5M | 531.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRAA | MNPR |
|---|---|---|
| Price | $17.04 | $61.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $24.33 | ★ $97.83 |
| AVG Volume (30 Days) | ★ 395.5K | 283.1K |
| Earning Date | 02-18-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,161,679,000.00 | N/A |
| Revenue This Year | $7.85 | N/A |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $12.29 | $22.50 |
| 52 Week High | $23.97 | $105.00 |
Technical Indicators
Market Signals| Indicator | PRAA | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 30.16 |
| Support Level | $17.29 | $63.73 |
| Resistance Level | $18.02 | $70.01 |
| Average True Range (ATR) | 0.53 | 4.83 |
| MACD | -0.08 | -0.68 |
| Stochastic Oscillator | 32.65 | 23.77 |
Price Performance
Historical ComparisonAbout PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.